Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

CTI to focus on Pixantrone and OPAXIO Approval and Commercialization

SEATTLE, Feb. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it exercised its option to sell its 50% ownership interest in the Zevalin joint venture to Spectrum Pharmaceuticals, Inc. (Spectrum) for $18 million. CTI and Spectrum established a joint venture in December 2008 to develop and commercialize Zevalin. At that time CTI contributed all of the Zevalin related assets to the joint venture and sold to Spectrum a 50% membership interest in the joint venture for $15 million, plus certain milestone payments.

The Company will focus its resources on the approval of pixantrone for relapsed aggressive non-Hodgkin's lymphoma (NHL) and OPAXIO for non-small cell lung and ovarian cancer. CTI estimates that as a result of the sale of the Zevalin interest it will reduce expenses by approximately $15 million annually from activities previously associated with Zevalin while providing CTI with non-dilutive source of operating capital.

"CTI continues to believe in the value of Zevalin as a commercially attractive product and effective form of cancer therapy; however, with the impressive clinical trial results for pixantrone and given the company's need for operating capital, we are compelled to exercise our option and focus our resources on pixantrone," noted James Bianco, MD, CEO of CTI. "CTI has been proud to have provided Zevalin to patients since we acquired it in December, 2007 and having the foresight to bring the first line consolidation for indolent NHL data to the FDA for potential label expansion in the front line consolidation setting. With the progress we made in removing many of the barriers that prevent its more widespread use, we are confident Spectrum will be able to ultimately make Zevalin a commercially attractive product."

At the closing of the sale of CTI's 50% m
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 Once ... to provide a larger packaged waste water treatment plant ... King Abdullah Economic City (KAEC). Two years ago Bioshaft ... Jeddah Gate Development, serving two residential towers with an ... is over a quarter million gallons per day and ...
(Date:12/17/2014)... AUSTIN, Texas , Dec. 16, 2014  Vermillion, ... company focused on gynecologic disease, today announced the next ... into a premier bio-analytics solutions provider with the naming ... to President and Chief Executive Officer, while current Chairman ... will continue to serve as Chairman. These changes are ...
(Date:12/15/2014)... December 15, 2014 METTLER TOLEDO ... PVM tool, ParticleView V19 with PVM technology ... probe-based particle vision and measurement tool continuously captures ... conditions. ParticleView V19 then automatically prepares a report ... particle size and concentration changes. This compelling blend ...
(Date:12/15/2014)... Denmark , Dec. 15, 2014  Ascendis ... innovative TransCon technology to address significant unmet medical ... its ongoing Phase 2 pediatric study to evaluate ... hormone deficiency, or GHD.  This interim analysis consists ... anticipated total enrollment in the study, completing all ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Inc. (Nasdaq: NXXI ), the developer and ... and Diabetes Essentials(R) brands that help consumers manage blood ... chronic joint pain, today announced financial results for the ... 2009.For the quarter the Company reported total revenues of ...
... (Nasdaq: BJGP ) ("BMP Sunstone" or the "Company") ... Healthcare Services,Conference, which will be held at the Waldorf-Astoria in ... Management is currently scheduled to present at 3:30 pm ... same day. , A webcast of ...
... Genesis HealthCare, a provider of long-term care services ... today that Wendy LaBate has been promoted to Senior ... In her new position, LaBate will be responsible for ... Regional Vice Presidents of Operations and Administrators in six ...
Cached Biology Technology:Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 2Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 3Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 4Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 5Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 6Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 7BMP Sunstone to Present at UBS Global Healthcare Services Conference 2Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area 2
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... they develop, vertebrate embryos form vertebrae in a ... that this process of body segmentation is controlled ... oscillating activity of certain genes within embryonic cells. ... timing system works. A new international ...
... Ind. -- Scientists at Indiana University and international collaborators ... a single molecule, producing a more effective therapy with ... obesity and related medical conditions. , The studies were ... Standiford H. Cox Distinguished Professor of Chemistry and the ...
... A new study demonstrates the dynamic role cilia play ... brain. Cilia are tiny hair-like structures on the surfaces ... radio antennae. In developing mouse embryos, researchers were ... migrate. The cilia appear to be receiving signals needed ...
Cached Biology News:Study sheds light on genetic 'clock' in embryonic cells 2Hormone combination effective and safe for treating obesity in mice 2Cilia guide neuronal migration in developing brain 2
... Ribonuclease Inhibitor is a recombinant protein that has ... RNA in the preparation of cDNA by reverse ... vitro protein synthesis. RNA Safe Inhibitor tightly binds ... broad range of eukaryotic RNases such as RNase ...
... Natural and Recombinant RNasin Ribonuclease Inhibitors ... the inhibition of eukaryotic RNases of the ... its inhibitory effect by noncovalently binding to ... value for the binding of RNasin Ribonuclease ...
...
Canine Aortic Smooth Muscle Cells (CnAOSMC) (>500,000 cells)...
Biology Products: